113: SPECIFIC TARGETING OF HER2-POSITIVE BREAST CANCER CELL LINE (SK-BR3) USING IDARUBICIN-LOADED ANTI-HER2 IMMUNOLIPOSOME

Cytotoxic chemotherapy drugs which are used for treating malignant cells cannot distinguish between normal and cancerous cells. This would lead to adverse side effects. Moreover, drug resistance is another major problem of the classical chemotherapy during the treatment period. Recently, various the...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMJ Open
Main Authors: Pourshohod, Aminollah, Zeinali, Majid, Afrakhte, Moslem, Jamalan, Mostafa
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2017
נושאים:
Abstracts from the 5th International Society for Evidence-Based Healthcare Congress, Kish Island, Ira
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5759544/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2016-015415.113
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים